Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM2THBX)

Drug Name

OM-174 Drug Info

Synonyms

UNII-HC3530GGGG; HC3530GGGG; Defoslimod [INN]; OM 174 lipid; 2-Deoxy-6-o-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate.; 2-Deoxy-6-O-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 9833422
CAS Number: CAS 171092-39-0
TTD Drug ID: DM2THBX

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 2 (TLR2)	TTY7ZHS	TLR2_HUMAN	Modulator	[2]
Toll-like receptor 4 (TLR4)	TTISGCA	TLR4_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Toll-like receptor 2 (TLR2)	DTT	TLR2	6.005	6.064	5.7	3.655
Toll-like receptor 4 (TLR4)	DTT	TLR4	5.853	5.555	6.158	5.82

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Toll-like receptor 2 (TLR2)	DTT	TLR2	1.75E-01	-0.48	-0.45
Toll-like receptor 4 (TLR4)	DTT	TLR4	5.26E-01	0.35	0.46

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01800812) Effects of OM-174 in Adult Patients With Solid Tumors. U.S. National Institutes of Health.
2	Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.